NIAID recently released its START study interim results

On 28 May 2015 the United States National Institute of Allergy and Infectious Diseases (NIAID) released interim results of its START (Strategic Timing of AntiRetroviral Treatment) study. 

Based on an interim review of study data, the independent data and safety monitoring board (DSMB) of START concluded that people living with HIV have a significantly lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, before their CD4+ T-cell count falls below lower levels. 

These results are consistent with the findings released in February 2015 from the TEMPRANO Study which showed that early treatment of HIV improves the health of PLHIV.